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Objective: The aim of the study was evaluating the diagnostic value of plasma matrix metalloproteinase-
(MMP)-2 and -9 and tissue inhibitor of MMP-1 (TIMP-1) for endoleak detection after endovascular
aneurysm repair (EVAR).
Report: Consecutive EVAR patients (n ¼ 17) with endoleak and matched controls without endoleak
(n ¼ 20) were prospectively enrolled. Increased levels of MMP-9 were observed in patients with endoleak
(P < 0.001). Regression analysis showed no signiﬁcant inﬂuence of age, sex or abdominal aortic aneurysm
(AAA) size. The receiver operating characteristic (ROC) curve of plasma MMP-9 levels showed that a cut-
off value of 55.18 ng ml1 resulted in 100% sensitivity and 96% speciﬁcity with an AUC value of 0.988
(P < 0.001) to detect endoleak.
Conclusions: Plasma MMP-9 levels appear to discriminate between patients with and without an
endoleak with high sensitivity and speciﬁcity.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Endoleak is the most common complication of endovascular
aneurysm repair (EVAR) with a reported incidence varying from 2%
to 45%.1 Re-interventions are frequently required since endoleak
may cause enlargement with eventual rupture of the aneurysm sac.
Computed tomography angiography (CTA) is considered the gold
standard for detection of these complications, despite known
disadvantages such as cumulative radiation dose, nephrotoxic
contrast agent and high costs.2 Therefore, a less harmful and less
costly alternative for follow-up after EVAR is desirable.
Increased circulating levels of plasma matrix metalloproteinase
(MMP)-2 and -9 and tissue inhibitor of MMP-1 (TIMP-1) are asso-
ciated with presence and size of abdominal aortic aneurysm
(AAA).3 It has been shown that decreased MMP levels during post-
EVAR surveillance might indicate successful EVAR whereas anartment of General Surgery,
ox 5800, 6202 AZ Maastricht,
875473.
ellenthal).
t.
ciety for Vascular Surgery. Publisheincrease may help to identify patients with aneurysm sac growth
and/or endoleakage.4,5 However, reports on the diagnostic value of
these biochemical assays are lacking and hence none of these
assays are clinically applied. The objective of this study was to
evaluate the potential clinical applicability of MMP-2 and -9 and
TIMP-1 as a diagnostic tool for endoleakage presence.
Report
Thirty-seven patients who underwent routine CTA follow-up
and blood sampling after EVAR were included in the study.
Plasma levels of MMP-2 and -9 and TIMP-1 were determined using
enzyme-linked immunosorbent assay (ELISA) (GE Healthcare/Life-
sciences, Upssala, Sweden). Seventeen patients had an endoleak as
detected on CTA, which included four type I, 12 type II and one type
III endoleak. The other 20 patients were matched controls. Initial
aneurysm diameter was larger in patients with endoleaks detected
(Table 1). Patients and aneurysm characteristics as well as plasma
levels of MMP-2 and -9 and TIMP-1 are listed in Table 1. Higher
MMP-9 levels were observed in patients with an endoleak asd by Elsevier Ltd. All rights reserved.
Table 1
Patient and aneurysm characteristics.
Endoleak  (n ¼ 20) Endoleak þ (n ¼ 17) P value
Male gender (%) 19 (95) 16 (94) ns
Ageeyears (mean (SD)) 74 (9.5) 73 (7.0) ns
Smoking history (%) 20 (100) 17 (100) ns
Current smokers (%) 5 (25) 4 (24)
Ex smokers (%) 15 (75) 13 (76)
Statin use (%) 7 (35) 11 (65) ns
Months between EVAR and CTA (mean (SD)) 18 (15) 21 (15) ns
Initial AP AAA diameter e mm (mean (SD)) 57 (17) 72 (19) 0.038
Right groin introduction of main device (%) 18 (90) 17 (100) ns
Neck diameter e mm (mean (SD)) 24 (4.2) 24 (3.7) ns
Neck length e mm (mean (SD)) 35 (14) 37 (16) ns
Unfavorable angulation of neck (%) 3 (15) 2 (12) ns
Diameter ipsilateral CIA e mm (mean (SD)) 17 (6.1) 15 (3.2) ns
Diameter contralateral CIA e mm (mean (SD)) 18 (7.3) 17 (4.5) ns
Tortuosity of iliac axis 3 (15) 4 (24) ns
Patent IMA (%) 5 (25) 4 (24) ns
MMP-2 (ng/mL) 1006.58 (285.76) 1110.37 (370.23) ns
MMP-9 (ng/mL) 25.02 (13.40) 89.54 (26.46) <0.001a
TIMP-1 (ng/mL) 138.14 (69.08) 142.51 (63.29) ns
AP ¼ Anterioreposterior, mm ¼ millimeter, SD ¼ standard deviation, CIA ¼ common iliac artery, IMA ¼ inferior mesenteric artery, MMP-2 ¼ matrix metalloproteinase -2,
MMP-9 ¼ matrix metalloproteinase-9, TIMP-1 ¼ tissue inhibitor of the matrix metalloproteinase type 1.
a Additional regression analysis showed that sex, age and AAA size (Dmax) do not inﬂuence the signiﬁcant effect of MMP-9 on predicting endoleak.
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receiver operating characteristic (ROC) curve represents the rela-
tionship between the speciﬁcity and the sensitivity of plasma
MMP-9 levels in detecting endoleak presence. The area under the
curve (AUC) was 0.99 with a sensitivity of 100% (95% conﬁdence
interval (CI) 80.5e100) and a speciﬁcity of 96% (95% CI 75.1e99.9)
using a cut-off value of 55.18 ng ml1. Plasma MMP-9 levels cannot
differentiate between different endoleak types. Anterioreposterior
aneurysmal diameter (Dmax) was signiﬁcantly larger in the endo-
leak group (72 vs. 57 mm; P ¼ 0.038); however, plasma MMP-9
levels were not associated with Dmax or intraluminal thrombus
(ILT) volume. Two patients who underwent intervention to elimi-
nate type II endoleak showed at 1 month post-intervention
a decrease in plasma MMP-9 levels (102.95e16.23 ng ml1 and
121.97 to 20.28 ng ml1). Furthermore, we determined MMP-9
levels in ﬂuid aspirated from the aneurysm sac of these patients,
showing greatly increased levels of MMP-9, 386.34 and
343.78 ng ml1, respectively.
Discussion
The present study showed that plasma MMP-9 levels can
accurately discriminate between patients with and without an
endoleakwith both high sensitivity and speciﬁcity. The ROC and the
AUC demonstrated that plasma MMP-9 is an excellent test to
determine endoleak presence. Implementing a blood test to
differentiate between patients with and without an endoleak is
clinically important. Patients without an endoleak could be spared
to undergo CTA with the aforementioned additional hazards and
cost.
Sangiorgi et al. and Lorelli et al. previously suggested that
plasma MMP-9 levels can be used to monitor the success of EVAR
procedures and showed proof of concept.4,5 The current study is the
ﬁrst to report the diagnostic value of theMMP-9 assay in post-EVAR
surveillance. We also showed that MMP-9 levels were associated
with endoleak presence and not with Dmax or ILT. Although this
case control study has a limited number of patients, sensitivity andspeciﬁcity rates are impressive and the conﬁdence intervals are
reassuring. Nevertheless, an adequately powered prospective
clinical trial is necessary to validate the applicability of plasma
MMP-9 levels to differentiate between patients with and without
endoleak in clinical practice and the potential role of plasma MMP-
9 levels in selecting EVAR patients requiring CTA. Furthermore,
standardisation of the assay (e.g., monoclonal antibody and cali-
brators) will be necessary for the application of one standard cut-
off value.
In conclusion, the present study suggests that plasma levels of
MMP-9 can accurately discriminate between patients with and
without an endoleak with both high sensitivity and speciﬁcity. A
prospective clinical trial to validate the clinical applicability of this
assay is in progress.
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